Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Nov;34(11):1132-40.
doi: 10.1002/phar.1483. Epub 2014 Sep 9.

Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide

Mariellen J Moore  1 , Yan Gong, Wei Hou, Karen Hall, Siegfried O F Schmidt, Robert Whitney Curry Jr, Amber L Beitelshees, Arlene Chapman, Stephen T Turner, Gary L Schwartz, Kent Bailey, Eric Boerwinkle, John G Gums, Rhonda M Cooper-DeHoff, Julie A Johnson
Affiliations
Randomized Controlled Trial

Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide

Mariellen J Moore et al. Pharmacotherapy. 2014 Nov.

Abstract

Study objective: To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).

Design: Randomized multicenter clinical trial.

Patients: A total of 735 white or African-American men and women with uncomplicated hypertension.

Measurements and main results: Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.

Conclusion: Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.

Trial registration: ClinicalTrials.gov NCT00246519.

Keywords: atenolol; hydrochlorothiazide; hyperglycemia; impaired fasting glucose; thiazide diuretics; β-Blockers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between model-predicted glucose and actual change in validation after treatment (a) after atenolol therapy; (b) after hydrochlorothiazide (HCTZ) therapy.
See this image and copyright information in PMC

References

    1. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7. - PubMed
    1. Dahl€of B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. - PubMed
    1. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]) Am J Cardiol. 2006;98:890–4. - PubMed
    1. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254–62. - PubMed
    1. Dahl€of B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrof-lumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906. - PubMed

Publication types

MeSH terms

Associated data